Square 1 Bank provided a $10 million credit facility to new client TissueTech. Proceeds will provide working capital for the company’s sales force expansion and pursuit of additional growth opportunities.

“We are pleased with the completion of this credit facility which will support current and future growth opportunities for TissueTech and its subsidiaries,” said Michael T. Cornelius, chief financial officer of TissueTech. “This additional capital will further support our efforts to develop and bring to market innovative, regenerative tissue therapies.”

“TissueTech’s strong management team and innovative breakthroughs in regenerative wound healing have positioned the company for tremendous success,” added Mara Huntington, managing director of Square 1 Bank’s East life sciences practice. “We are proud to be the company’s banking partner and look forward to supporting its growth for years to come.”

TissueTech is a provider of regenerative amniotic tissue-based products for use in the ophthalmology, optometry, musculoskeletal and wound care markets.